Fate Therapeutics Inc.

1.84-0.0800-4.17%Vol 1.81M1Y Perf -91.53%
Oct 3rd, 2023 16:00 DELAYED
BID1.80 ASK1.98
Open1.90 Previous Close1.92
Pre-Market- After-Market1.80
 - -  -0.04 -2.09%
Target Price
54.44 
Analyst Rating
Moderate Buy 2.48
Potential %
2.86K 
Finscreener Ranking
★★★★+     56.32
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.53
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     66.69
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
-0.23 
Earnings Rating
Neutral
Market Cap181.35M 
Earnings Date
2nd Nov 2023
Alpha-0.02 Standard Deviation0.19
Beta1.47 

Today's Price Range

1.761.90

52W Range

1.8923.96

5 Year PE Ratio Range

-21.00-6.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.95%
1 Month
-31.67%
3 Months
-60.17%
6 Months
-66.95%
1 Year
-91.53%
3 Years
-94.96%
5 Years
-88.05%
10 Years
-72.17%

TickerPriceChg.Chg.%
FATE1.84-0.0800-4.17
AAPL172.40-1.3500-0.78
GOOG133.30-1.8700-1.38
MSFT313.39-8.4100-2.61
XOM115.830.20000.17
WFC38.67-0.9400-2.37
JNJ155.340.19000.12
FB196.640.99000.51
GE107.76-1.0300-0.95
JPM142.71-1.0600-0.74
Financial StrengthValueIndustryS&P 500US Markets
5.00
5.20
0.17
0.21
-275.20
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-447.00
-430.90
-864.70
-
RevenueValueIndustryS&P 500US Markets
51.94M
0.53
101.21
78.28
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.58-0.546.90
Q01 2023-0.55-0.1965.45
Q04 2022-0.86-0.5832.56
Q03 2022-0.93-0.867.53
Q02 2022-0.86-0.798.14
Q01 2022-0.78-0.6812.82
Q04 2021-0.68-0.72-5.88
Q03 2021-0.58-0.571.72
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.59-1.72Negative
12/2023 QR-0.62-10.71Negative
12/2023 FY-1.93-0.52Negative
12/2024 FY-2.21-6.25Negative
Next Report Date2nd Nov 2023
Estimated EPS Next Report-0.59
Estimates Count9
EPS Growth Next 5 Years %22.20
Volume Overview
Volume1.81M
Shares Outstanding98.56K
Shares Float93.59M
Trades Count8.22K
Dollar Volume3.31M
Avg. Volume2.28M
Avg. Weekly Volume1.43M
Avg. Monthly Volume3.21M
Avg. Quarterly Volume2.21M

Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 1.92 per share at the end of the most recent trading day (a -9.43% change compared to the prior day closing price) with a volume of 1.52M shares and market capitalization of 181.35M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.

The one-year performance of Fate Therapeutics Inc. stock is -91.53%, while year-to-date (YTD) performance is -80.97%. FATE stock has a five-year performance of -88.05%. Its 52-week range is between 1.89 and 23.96, which gives FATE stock a 52-week price range ratio of -0.23%

Fate Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.80, a price-to-sale (PS) ratio of 9.86, a price to cashflow ratio of -, a PEG ratio of -0.06, a ROA of -37.13%, a ROC of -40.49% and a ROE of -51.73%. The company’s profit margin is -%, its EBITDA margin is -430.90%, and its revenue ttm is $51.94 Million , which makes it $0.53 revenue per share.

Of the last four earnings reports from Fate Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.59 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is 02nd Nov 2023.

The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Moderate Buy (2.48), with a target price of $54.44, which is +2 858.70% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fate Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.58, ATR14 : 0.19, CCI20 : -124.97, Chaikin Money Flow : -0.24, MACD : -0.25, Money Flow Index : 24.64, ROC : -18.64, RSI : 31.16, STOCH (14,3) : 4.05, STOCH RSI : 0.14, UO : 36.16, Williams %R : -95.95), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $580), Bahram Valamehr (Sold 10 917 shares of value $57 205 ), Chu Yu-Waye (Sold 10 357 shares of value $57 651 ), Cindy R. Tahl (Sold 11 553 shares of value $60 538 ), Cindy Tahl (Sold 11 553 shares of value $60 538 ), Dulac Edward (Sold 7 331 shares of value $38 414 ), Dulac Edward J III (Sold 5 182 shares of value $25 029 ), Edward J. Dulac (Sold 7 331 shares of value $38 414 ), J. Scott Wolchko (Sold 45 907 shares of value $240 553 ), John D. Mendlein (Option Excercise at a value of $38 992), Mark Plavsic (Sold 3 418 shares of value $17 910 ), Plavsic Mark (Sold 3 418 shares of value $17 910 ), Powl Brian T. (Sold 3 854 shares of value $18 769 ), Valamehr Bahram (Option Excercise at a value of $580), Valamehr Bahram (Sold 10 917 shares of value $57 205 ), Wolchko J. (Sold 45 907 shares of value $240 553 ), Xu Yuan (Sold 4 092 shares of value $21 652 ), Yu-Waye Chu (Sold 10 357 shares of value $57 651 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (33.33 %)
7 (31.82 %)
6 (28.57 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
12 (57.14 %)
13 (59.09 %)
13 (61.90 %)
Moderate Sell
1 (4.76 %)
1 (4.55 %)
1 (4.76 %)
Strong Sell
1 (4.76 %)
1 (4.55 %)
1 (4.76 %)
Summary RatingModerate Buy
2.48
Moderate Buy
2.50
Moderate Buy
2.57

Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

CEO: J. Scott Wolchko

Telephone: +1 858 875-1800

Address: 3535 General Atomics Court, San Diego 92121, CA, US

Number of employees: 279

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

58%42%

 

TipRanks News for FATE

Thu, 10 Aug 2023 07:26 GMT Fate Therapeutics (FATE) Gets a Buy from Barclays

- TipRanks. All rights reserved.

Wed, 09 Aug 2023 04:10 GMT Analysts Top Healthcare Picks: Fate Therapeutics (FATE), Royalty Pharma (RPRX)

- TipRanks. All rights reserved.

News

Stocktwits